Literature DB >> 16455833

Volatile organic compounds in the exhaled breath of young patients with cystic fibrosis.

M Barker1, M Hengst, J Schmid, H-J Buers, B Mittermaier, D Klemp, R Koppmann.   

Abstract

Inflammatory mediators in the exhaled breath are receiving growing medical interest as noninvasive disease markers. Volatile organic compounds have been investigated in this context, but clinical information and methodological standards are limited. The levels of ethane, propane, n-pentane, methanol, ethanol, 2-propanol, acetone, isoprene, benzene, toluene, dimethyl sulphide (DMS) and limonene were measured in repeated breath samples from 20 cystic fibrosis patients and 20 healthy controls (aged 8-29 yrs). Three end-exhaled and one ambient air sample were collected per person and analysed on a customised gas chromatography system. Intra-subject coefficients of variation ranged between 9 and 34%, and hydrocarbon breath levels were influenced by their inspired concentrations. The alveolar gradient for pentane was higher in cystic fibrosis patients than in healthy controls (0.36 versus 0.21 ppb) and inversely proportional to forced expiratory volume in one second; highest values were observed in patients with pulmonary exacerbations (0.73 versus 0.24 ppb). Cystic fibrosis patients also exhibited a lower output of DMS (3.9 versus 7.6 ppb). Group differences were not significant for ethane and the remaining substances. It was concluded that chemical breath analysis for volatile organic compounds is feasible and may hold potential for the noninvasive diagnosis and follow-up of inflammatory processes in cystic fibrosis lung disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16455833     DOI: 10.1183/09031936.06.00085105

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  36 in total

1.  Application of femtosecond laser mass spectrometry to the analysis of volatile organic compounds.

Authors:  Min Liu; Chengyin Wu; Zhifeng Wu; Hong Yang; Qihuang Gong; Wei Huang; Tong Zhu
Journal:  J Am Soc Mass Spectrom       Date:  2010-02-18       Impact factor: 3.109

2.  A rapid method for breath analysis in cystic fibrosis patients.

Authors:  R Kramer; A Sauer-Heilborn; T Welte; C A Guzman; M G Höfle; W-R Abraham
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-11-28       Impact factor: 3.267

3.  Exhaled breath analysis: The new interface between medicine and engineering.

Authors:  Alquam Mashir; Raed A Dweik
Journal:  Adv Powder Technol       Date:  2009-09       Impact factor: 4.833

4.  A Winogradsky-based culture system shows an association between microbial fermentation and cystic fibrosis exacerbation.

Authors:  Robert A Quinn; Katrine Whiteson; Yan-Wei Lim; Peter Salamon; Barbara Bailey; Simone Mienardi; Savannah E Sanchez; Don Blake; Doug Conrad; Forest Rohwer
Journal:  ISME J       Date:  2015-03-17       Impact factor: 10.302

5.  Analysis of volatile organic compounds from deep airway in the lung through intubation sampling.

Authors:  Wei Xu; Jin Zhang; Houwen Ding; Yueting Ding; Xue Zou; Min Yang; Qiang Zhou; Zhou Liu; Ling Zheng; Heping Zuo; Dianlong Ge; Qiangling Zhang; Chaoqun Huang; Chengyin Shen; Yannan Chu
Journal:  Anal Bioanal Chem       Date:  2022-08-26       Impact factor: 4.478

Review 6.  Novel end points for clinical trials in young children with cystic fibrosis.

Authors:  Shannon J Simpson; Lauren S Mott; Charles R Esther; Stephen M Stick; Graham L Hall
Journal:  Expert Rev Respir Med       Date:  2013-06       Impact factor: 3.772

Review 7.  Exhaled breath analysis for lung cancer.

Authors:  Annette G Dent; Tom G Sutedja; Paul V Zimmerman
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

Review 8.  Assessment, origin, and implementation of breath volatile cancer markers.

Authors:  Hossam Haick; Yoav Y Broza; Pawel Mochalski; Vera Ruzsanyi; Anton Amann
Journal:  Chem Soc Rev       Date:  2013-12-04       Impact factor: 54.564

9.  Exhaled volatile organic compounds analysis in clinical pediatrics: a systematic review.

Authors:  Rosa A Sola Martínez; José M Pastor Hernández; Óscar Yanes Torrado; Manuel Cánovas Díaz; Teresa de Diego Puente; María Vinaixa Crevillent
Journal:  Pediatr Res       Date:  2020-09-12       Impact factor: 3.756

Review 10.  Clinical use of exhaled volatile organic compounds in pulmonary diseases: a systematic review.

Authors:  Kim D G van de Kant; Linda J T M van der Sande; Quirijn Jöbsis; Onno C P van Schayck; Edward Dompeling
Journal:  Respir Res       Date:  2012-12-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.